Home » Stocks » NVRO

Nevro Corp. (NVRO)

Stock Price: $158.18 USD 1.44 (0.92%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 5.50B
Revenue (ttm) 363.19M
Net Income (ttm) -87.74M
Shares Out 34.63M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $158.18
Previous Close $156.74
Change ($) 1.44
Change (%) 0.92%
Day's Open 157.08
Day's Range 156.82 - 159.42
Day's Volume 235,843
52-Week Range 111.87 - 188.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

Investors' confidence is high in Nevro (NVRO) stock, courtesy of its solid prospects.

1 month ago - Zacks Investment Research

Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.

1 month ago - Zacks Investment Research

Nevro (NVRO) delivered earnings and revenue surprises of 1.16% and 4.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

REDWOOD CITY, Calif., May 5, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, toda...

1 month ago - PRNewsWire

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

REDWOOD CITY, Calif., April 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, t...

1 month ago - PRNewsWire

REDWOOD CITY, Calif., April 26, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today...

1 month ago - PRNewsWire

REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, t...

1 month ago - PRNewsWire

REDWOOD CITY, Calif., April 13, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, t...

2 months ago - PRNewsWire

REDWOOD CITY, Calif., April 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

2 months ago - PRNewsWire

REDWOOD CITY, Calif., April 5, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

2 months ago - PRNewsWire

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

3 months ago - Zacks Investment Research

Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which beat the est...

3 months ago - Benzinga

REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

3 months ago - PRNewsWire

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

4 months ago - PRNewsWire

REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

4 months ago - PRNewsWire

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

Other stocks mentioned: BJ, FATE, GLNG, GTLS, HCAT, IIVI, LPSN ...
4 months ago - Kiplinger

Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.

5 months ago - Zacks Investment Research

Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.

5 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

5 months ago - PRNewsWire

REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

5 months ago - PRNewsWire

Nevro has been prospering in its chosen specialty of opioid-free pain relief. Nevro's Omnia launch has been dampened by the pandemic; expect good things as the pandemic moves to the rear.

5 months ago - Seeking Alpha

REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

5 months ago - PRNewsWire

MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent in...

Other stocks mentioned: BSX
5 months ago - PRNewsWire

REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

5 months ago - PRNewsWire

Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.

6 months ago - Zacks Investment Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

6 months ago - PRNewsWire

REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, to...

6 months ago - PRNewsWire

REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, an...

6 months ago - PRNewsWire

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

7 months ago - Zacks Investment Research

Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Nevro (NVRO) delivered earnings and revenue surprises of 50.85% and 4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.

7 months ago - Zacks Investment Research

Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.

8 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- Nevro Corp.

8 months ago - PRNewsWire

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

9 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Sept. 1, 2020 /PRNewswire/ -- Nevro Corp.

9 months ago - PRNewsWire

A Relative Strength Rating upgrade for Nevro shows improving technical performance.

9 months ago - Investors Business Daily

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

10 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp.

10 months ago - PRNewsWire

Nevro Corp (NVRO) CEO Keith Grossman on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

REDWOOD CITY, Calif., July 20, 2020 /PRNewswire/ -- Nevro Corp.

10 months ago - PRNewsWire

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

About NVRO

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force... [Read more...]

Industry
Medical Devices
IPO Date
Nov 6, 2014
CEO
D.Keith Grossman
Employees
843
Stock Exchange
NYSE
Ticker Symbol
NVRO
Full Company Profile

Financial Performance

In 2020, Nevro Corp.'s revenue was $362.05 million, a decrease of -7.23% compared to the previous year's $390.26 million. Losses were -$83.07 million, -19.89% less than in 2019.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for Nevro Corp. stock is "Buy." The 12-month stock price forecast is 200.17, which is an increase of 26.55% from the latest price.

Price Target
$200.17
(26.55% upside)
Analyst Consensus: Buy